--- title: Fibromyalgia and Sexual Functıonal Dısorder and Sexual Therapy nct_id: NCT05272345 overall_status: ACTIVE_NOT_RECRUITING phase: NA sponsor: Kanuni Sultan Suleyman Training and Research Hospital study_type: INTERVENTIONAL primary_condition: Fibromyalgia countries: Turkey (Türkiye) canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05272345.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05272345" ct_last_update_post_date: 2024-07-18 last_seen_at: "2026-05-12T06:26:07.713Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Fibromyalgia and Sexual Functıonal Dısorder and Sexual Therapy **Official Title:** Follow-Up Wıth Dıagnosıs Of Fıbromyalgıa In Patıents Wıth Sexual Functıonal Dısorder Evaluatıon Of Sexual Therapy And Post-Therapy Fıbromyalgıa **NCT ID:** [NCT05272345](https://clinicaltrials.gov/study/NCT05272345) ## Key Facts - **Status:** ACTIVE_NOT_RECRUITING - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 30 - **Lead Sponsor:** Kanuni Sultan Suleyman Training and Research Hospital - **Conditions:** Fibromyalgia, Sexual Dysfunction - **Start Date:** 2022-02-14 - **Completion Date:** 2025-12-14 - **CT.gov Last Update:** 2024-07-18 ## Brief Summary investigators aim to re-evaluate the findings of Fibromyalgia in patients whose FSFI scores return to normal levels after sexual therapy, by identifying patients with sexual dysfunction according to the FSFI scale applied in patients investigators followed up with a diagnosis of fibromyalgia, and when investigators consulted with obstetricians. ## Detailed Description Apart from routine Fibromyalgia treatments, investigators think that Fibromyalgia patients should be evaluated in detail in terms of sexual dysfunction, and better results will be obtained by adding sexual therapy to the treatment in patients with FSFI score below 26.55. In the current literature review, investigators have seen that there is no study on the evaluation of fibromyalgia before and after sexual therapy. investigators think that our study will be a pioneer in terms of showing the importance of the multidisciplinary approach in the treatment of Fibromyalgia. investigators foresee that sexuality is still a subject that is avoided to be talked about due to the cultural infrastructure of developing countries, and that Fibromyalgia will actually decrease with the regulation of sexual life. investigators believe that more comprehensive studies with this perspective will develop a multidisciplinary approach in Fibromyalgia. ## Eligibility - **Minimum age:** 15 Years - **Maximum age:** 49 Years - **Sex:** FEMALE - **Healthy Volunteers:** Yes ``` Inclusion Criteria: * Follow-up with a diagnosis of fibromyalgia * Reproductive age (15-49 years) * Women with sexual dysfunction (FSFI score \< 26.55) Exclusion Criteria: * Women Wıth Ibromyalgıa Wıthout Sexual Dysfunction * Women Wıth A Score Greater 26.55 Wıthout Therapy ``` ## Arms - **Fibromyalgia status before sexual therapy/ Fibromyalgia condition after sex therapy** (EXPERIMENTAL) — * Women with sexual dysfunction (FSFI score \< 26.55) in reproductive age (15-49 years) followed up with a diagnosis of fibromyalgia * Women with sexual dysfunction (FSFI score \< 26.55) in reproductive age (15-49 years) followed up with a diagnosis of fibromyalgia and who were reevaluated for fibromyalgia after sexual therapy was given ## Interventions - **sexual therapy** (PROCEDURE) — In sexual therapy; A total of 4 sessions of therapy were initiated with the patients, one session per week for 1 month. ## Primary Outcomes - **VAS evaluation results for pain before sexual therapy in patients with fibromyalgia** _(time frame: 6 months)_ — Evaluation results of women with fibromyalgia diagnosis with VAS SCAL VAS SCALE; THE PATIENT IS REQUESTED TO VALUE THE PAIN BETWEEN 0-10. 0 ; NO PAIN 10: SEVERE PAIN - **VAS evaluation results for pain after sexual therapy in patients with fibromyalgia** _(time frame: 6 months)_ — Evaluation results of women with fibromyalgia diagnosis with VAS SCAL after sexual therapy VAS SCALE; THE PATIENT IS REQUESTED TO VALUE THE PAIN BETWEEN 0-10. 0 ; NO PAIN 10: SEVERE PAIN - **FSFI scores before sexual therapy in patients with fibromyalgia** _(time frame: 6 months)_ — Evaluation results of women with fibromyalgia diagnosis with FSFI SCAL \* The FSFI questionnaire consists of 19 questions; It evaluates 6 main factors as sexual desire, sexual arousal, lubrication, orgasm, satisfaction and pain/discomfort. The highest total raw score that can be obtained in this scale is 95, the lowest raw score is 4, and the highest score is 36 after the product of the coefficients, and the lowest score is 2. Effect coefficients used for scoring the whole scale; 0.6 for sexual desire, 0.3 for sexual arousal and lubrication, and 0.4 for orgasm, satisfaction, and pain/discomfort. A FSFI score below 26.55 was defined as compatible with sexual dysfunction. - **FSFI scores after sexual therapy in patients with fibromyalgia** _(time frame: 6 months)_ — Evaluation results of women with fibromyalgia diagnosis with FSFI SCAL after sexual therapy \* The FSFI questionnaire consists of 19 questions; It evaluates 6 main factors as sexual desire, sexual arousal, lubrication, orgasm, satisfaction and pain/discomfort. The highest total raw score that can be obtained in this scale is 95, the lowest raw score is 4, and the highest score is 36 after the product of the coefficients, and the lowest score is 2. Effect coefficients used for scoring the whole scale; 0.6 for sexual desire, 0.3 for sexual arousal and lubrication, and 0.4 for orgasm, satisfaction, and pain/discomfort. A FSFI score below 26.55 was defined as compatible with sexual dysfunction. ## Locations (2) - Acıbadem University Atakent Hospital, Department of Obstetrics and Gynecology,, Istanbul, Turkey (Türkiye) - Pınar Kadiroğulları, Istanbul, Turkey (Türkiye) ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.acıbadem university atakent hospital, department of obstetrics and gynecology,|istanbul||turkey (türkiye)` — added _(2026-05-12)_ - `locations.pınar kadiroğulları|istanbul||turkey (türkiye)` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT05272345.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT05272345* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*